Quick Answer
KalVista Pharmaceuticals, Inc. reported R&D Expense of $71.71 million for fiscal year 2025.
KalVista Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $71.71M | -16.8% |
| 2024 | $86.17M | +7.3% |
| 2023 | $80.28M | +14.4% |
| 2022 | $70.17M | +70.0% |
| 2021 | $41.29M | +2.7% |
| 2020 | $40.19M | +14.8% |
| 2019 | $35.02M | +92.0% |
| 2018 | $18.24M | +44.0% |
| 2017 | $12.67M | -13.6% |
| 2016 | $14.66M | -9.5% |
| 2015 | $16.20M | +95.5% |
| 2015 | $8.29M | -0.1% |
| 2014 | $8.29M | +96.1% |
| 2013 | $4.23M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.99M | -35.8% | -20.9% |
| July 31, 2025 | $15.16M | -43.0% | +20.4% |
| January 31, 2025 | $12.59M | -44.1% | -24.2% |
| October 31, 2024 | $16.61M | -13.0% | -11.1% |
| September 30, 2024 | $18.68M | — | -29.8% |
| July 31, 2024 | $26.61M | +37.8% | +18.2% |
| January 31, 2024 | $22.52M | +12.3% | +18.0% |
| October 31, 2023 | $19.09M | +5.6% | -1.1% |
- KalVista Pharmaceuticals, Inc. showed a decrease of -16.8% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, KalVista Pharmaceuticals, Inc.’s r&d expense has grown by 1595.6% (from $4.23 million to $71.71 million).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: